This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy

This study has been completed.
Information provided by:
Cytos Biotechnology AG Identifier:
First received: December 1, 2008
Last updated: November 11, 2010
Last verified: November 2010
The purpose of the study is to test whether vaccinations with CYT003-QbG10 can improve allergy symptoms in patients with house dust mite allergy. The active treatment will be compared against placebo.

Condition Intervention Phase
Rhinoconjunctivitis Allergies Drug: CYT003-QbG10 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind, Placebo-controlled Dose-finding Study With CYT003-QbG10 in Adult Patients With Rhinoconjunctivitis Due to House Dust Mite Allergy

Resource links provided by NLM:

Further study details as provided by Cytos Biotechnology AG:

Primary Outcome Measures:
  • Rhinoconjunctivitis symptom and medication scores [ Time Frame: Pre- / Post-Treatment ]

Estimated Enrollment: 300
Study Start Date: November 2008
Study Completion Date: November 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: CYT003-QbG10
subcutaneous injection
Experimental: 2 Drug: CYT003-QbG10
subcutaneous injection
Placebo Comparator: 3 Drug: Placebo
subcutaneous injection


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Perennial allergic rhinoconjunctivitis due to clinically relevant allergy towards house dust mite allergens
  • Further criteria as defined in the study protocol

Exclusion Criteria:

  • Clinically manifested seasonal allergy/-ies which is/are expected to interfere with the patient's study treatment schedule and/or assessments
  • Clinically relevant perennial allergy/-ies other than house dust mites allergy
  • Contraindication to any study test or procedure
  • Further criteria as defined in the study protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00800332

Cytos Investigator Sites
Paide, Tartu, Tallin, Rakvere, Estonia
Cytos Investigator Sites
Fulda, Dresden, Ulm, Rodgau, Kassel, Eisenach, Germany
Cytos Investigator Sites
Wiesbaden, Frankfurt/M, Leipzig, Jena, Hamburg, Dulmen, Germany
Cytos Investigator Sites
N. Faliro, Hiraklion, Athens, Greece
Cytos Investigator Sites
Riga, Rezekne, Latvia
Cytos Investigator Sites
Vilnius, Kaunas, Klaipeda, Lithuania
Cytos Investigator Sites
Galati, Cluj Napoca, Bahia Mare, Brasov, Piesti, Romania
Cytos Investigator Sites
Targu Mures, Bukarest, Craiova, Iasi, Romania
Sponsors and Collaborators
Cytos Biotechnology AG
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Clinical Development, Cytos Biotechnology Identifier: NCT00800332     History of Changes
Other Study ID Numbers: CYT003-QbG10 09
Study First Received: December 1, 2008
Last Updated: November 11, 2010

Keywords provided by Cytos Biotechnology AG:
Rhinoconjunctivitis due to house dust mite allergy

Additional relevant MeSH terms:
Immune System Diseases
Conjunctival Diseases
Eye Diseases processed this record on September 21, 2017